<?php
include_once('.././common.php');
include_once(G5_PATH.'/head2.php');
?>

<div id="patients" class="main">
	<section class="visual">
		<div class="inner">
			<div class="visual-txt">
				<h2>Regdanvimab</h2>
				<h3>IV injection 960mg/16mL</h3>
				<p>
					Regdanvimab is authorized for use under an EUA for the treatment of mild to moderate<br class="pc-b">
					COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at<br class="pc-b"> 
					high risk for progressing to severe COVID-19 and/or hospitalization
				</p>
			</div>
			<!--visual-txt-->
			<ul class="about-ico">
				<li>
					<div class="icon"><img src="/img/icon1_01.png"></div>
					<p>Fact Sheet for Patients<br>and Caregivers</p>
				</li>
				<li>
					<div class="icon"><img src="/img/icon1_02.png"></div>
					<p>Fact Sheet for Healthcare<br>Providers </p>
				</li>
				<li>
					<div class="icon"><img src="/img/icon1_03.png"></div>
					<p>FDA Letter of<br>Authorization</p>
				</li>
			</ul>
		</div>
	</section>
	<!--visual-->
	<section id="sec01" class="cont-a">
		<div class="inner">
			<div class="cont-sec">
				<h2 class="cont-tit">Important facts about Regdanvimab (CT-P59)</h3>
				<p>
					Regdanvimab is authorized for use under an EUA for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
				</p>
				<p>
					<ul class="cont-list">
						<li>Regdanvimab has not been been approved, but has been authorized for emergency use by FDA</li>
					</ul>
				</p>
				<p>
					For information on the authorized use of regdanvimab and mandatory requirements under the Emergency Use Authorization, please review the
				</p>
				<p>
					<a href="#" target="_blank" class="p-gr ud-line">
						- Fact Sheet for patients<i class="fas fa-external-link-alt"></i>
					</a><br>
					<a href="#" target="_blank" class="p-gr ud-line">
						- Fact Sheet for patients, Parents and Caregivers (English)<i class="fas fa-external-link-alt"></i>  
					</a><br>
					<a href="#" target="_blank" class="p-gr ud-line">
						- Fact Sheet for patients, Parents and Caregivers (Spanish)<i class="fas fa-external-link-alt"></i>
					</a>	
				</p>
			</div>
			<!--cont-sec-->
			<div class="img-sec">
				<img src="/img/item_img.png">
			</div>
			<!--img-sec-->	
		</div>
	</section>
	<!--cont-a-->
	<section id="sec02" class="cont-b">
		<div class="inner">
			<h2 class="cont-tit">Autorized Use and Safety Information</h2>
			<div class="cont-sec">
				<div class="cont-box">
					<ul class="cont-list">
						<li>
							Regdanvimab is an investigational medicine used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and pediatric patients 
							(12 years of age and older who weigh at least 88 pounds (40 kg)), and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.
						</li>
						<li>
							Regdanvimab has not been approved, but has been authorized for emergency use by FDA<br>
							Regdanvimab is investigational because it is still being studied. There is limited information known about the safety or effectiveness of 
							using regdanvimab to treat people with COVID-19.
						</li>
					</ul>
				</div>
			</div>
			<!---->
			<div class="cont-sec">
				<h3 class="sub-tit">Definition of high risk</h3>
				<div class="explan cont-indt">
					<p> patients who are <b class="p-bk">≥50 years of age AND have pneumonia but no signs of severe pneumonia</b> and do <b class="p-bk">not require supplemental oxygen therapy.</b></p>
				</div>
			</div>
			<!---->
			<div class="cont-sec">
				<h3 class="sub-tit">Limitations of Authorized Use</h3>
				<div class="cont-indt">
					<ul class="cont-list">
						<li>
							<p class="p-bk mg20" style="display:block;">Regdanvimab is not authorized for use in patients : </p>
							<div class="cont-box">
								<ul class="s-cont-list">
									<li>who are hospitalized due to COVID-19, OR </li>
									<li>who require oxygen therapy due to COVID-19, OR</li>
									<li>who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity. </li>
								</ul>
							</div>
						</li>
						<li class="blt-none p-bk">Benefit of treatment with regdanvimab has not been studied in patients hospitalized due to COVID-19</li>
					</ul>
				</div>
			</div>
			<!---->
			<div class="cont-sec">
				<h3 class="sub-tit">Warnings and Precautions</h3>
				<div class="cont-indt">
					<ul class="cont-list">
						<li>
							There are limited clinical data available for regdanvimab. Serious and unexpected adverse events may occur that have not been 
							previously reported with  regdanvimab use.
						</li>
					</ul>
					<div class="s-cont-sec">
						<b class="p-gr mg06">1) Hypersensitivity Reactions including Anaphylaxis and Infusion-Related Reactions</b>
						<ul class="cont-list cont-indt">
							<li>
								There is a potential for serious hypersensitivity reactions, including anaphylaxis, with administration of regdanvimab. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.
							</li>
							<li>
								Infusion-related reactions have been observed with administration of regdanvimab.
							</li>
							<li>
								Signs and symptoms of infusion related reactions may include:<br>
								fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness.
							</li>
							<li>
								If an infusion-related reaction occurs, consider slowing or stopping the infusion and administer appropriate medications and/or supportive care.
							</li>
						</ul>
					</div>
					<!--1-->
					<div class="s-cont-sec">
						<b class="p-gr mg06">2) Limitations of Benefit and Potential for Risk in Patients with Severe COVID-19</b>
						<ul class="cont-list cont-indt">
							<li class="mg20">
								Benefit of treatment with regdanvimab has not been studied in patients hospitalized due to COVID-19. Therefore, regdanvimab is not authorized for use in patients<br>[see Limitations of Authorized Use (1)]:
							</li>
							<li class="blt-none">
								<div class="cont-box">
									<ul class="s-cont-list">
										<li>who are hospitalized due to COVID-19, OR </li>
										<li>who require oxygen therapy due to COVID-19, OR </li>
										<li>who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity. </li>
									</ul>
								</div>
							</li>
						</ul>
					</div>
					<!--2-->
				</div>
			</div>
			<!---->
			<div class="cont-sec">
				<h3 class="sub-tit">Specific populations</h3>
				<div class="cont-indt">
					<div class="s-cont-sec">
						<b class="p-gr mg06">1) Pregnancy</b>
						<ul class="cont-list cont-indt">
							<li>
								There are insufficient data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. 
								Regdanvimab should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.
							</li>
						</ul>
					</div>
					<!--1-->
					<div class="s-cont-sec">
						<b class="p-gr mg06">2) Breastfeeding</b>
						<ul class="cont-list cont-indt">
							<li>
								There are no available data on the presence of regdanvimab in human or animal milk, the effects on the breastfed infant, or the effects on milk production. 
							</li>
							<li>
								Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.
							</li>
						</ul>
					</div>
					<!--2-->
					<div class="explan">
						<p class="p-bk">
							Healthcare providers should review the Fact Sheet for information on the authorized use of regdanvimab and mandatory requirements of the EUA.<br> 
							Please see the <b class="ud-line">FDA Letter of Authorization, Fact Sheet for Healthcare Providers,</b> and <b class="ud-line">Fact Sheet for Patients, Parents and Caregivers (English)</b> or <b class="ud-line">Fact Sheet for Patients, 
							Parents and Caregivers (Spanish).</b>
						</p>
					</div>
				</div>
			</div>
			<!---->
		</div>
	</section>-->
	<section id="sec03" class="cont-c">
		<div class="inner">
			<h2 class="cont-tit">What is COVID-19?</h3>
			<div class="explan">
				<p>
					Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus, called severe acute respiratory<br> 
					syndrome coronavirus 2 (SARS-CoV-2), that can spread from person to person.
				</p>
				<p>
					COVID-19 symptoms can range from mild (or no symptoms) to severe illness.<br>
					Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease,<br> 
					and cancer are more likely to develop serious illness.
				</p>
			</div>
			<!--explan-->
		</div>
	</section>
	<!--cont-b-->
	<section id="sec04" class="cont-d">
		<div class="inner">
			<h2 class="cont-tit">What are the symptoms of COVID-19?</h3>
			<div class="explan">
				<p>
					The symptoms of COVID-19 include fever, cough, and shortness of breath, which may appear 2 to 14 days after exposure.<br>
					Serious illness including breathing problems can occur and may cause your other medical conditions to become worse.
				<p>
				<b class="p-gr">Speak to your healthcare provider by telephone, if you have concerns about your medication or symptoms</b>
			</div>
			<!--explan-->
			<ul class="img-list">
				<li>
					<div class="img-sec"><img src="/img/pt/sptm_img01.png"></div>
					<p>Fever (high temperature)</p>
				</li>
				<li>
					<div class="img-sec"><img src="/img/pt/sptm_img02.png"></div>
					<p>Cough</p>
				</li>
				<li>
					<div class="img-sec"><img src="/img/pt/sptm_img03.png"></div>
					<p>Shortness of breath</p>
				</li>
			</ul>
		</div>
	</section>
	<!--cont-c-->
	<section id="sec05" class="cont-e">
		<div class="inner">
			<h2 class="cont-tit">Who is regdanvimab for?</h2>
			<div class="explan">
				<p>
					Regdanvimab should be administered as soon as possible after positive viral test for SARS-CoV-2 and within 10 days of symptom onset in adults who are at high risk for progressing to severe COVID‑19 and/or hospitalization.  
				</p>
				<p>
					High risk is defined as patients who are <b class="p-bk">≥50 years of age AND have pneumonia but no signs of severe pneumonia and do not require supplemental oxygen therapy.</b>
				</p>
			</div>
		</div>
	</section>
</div> 
<?php
include_once(G5_PATH.'/tail.php');
?>